PurpleAI Receives Medical Device Approval for Cerebral Aneurysm Diagnostic AI

Improves Physicians' Diagnostic Sensitivity by Over 10 Percentage Points
Korea's First CT Image-Based AI Solution for Cerebral Aneurysm Detection

PurpleAI's artificial intelligence (AI) solution for diagnosing cerebral aneurysms has received Class III medical device approval from the Ministry of Food and Drug Safety.

A cerebral aneurysm is a condition in which the wall of a cerebral artery weakens and balloons out, resembling a balloon or a berry. If it ruptures, it can cause severe cerebral hemorrhage and may lead to death, making early and accurate diagnosis and management crucial.

PurpleAI's cerebral aneurysm diagnostic AI solution automatically detects suspected aneurysm areas in patients' vascular CT images, helping medical professionals make faster and more accurate diagnoses. Clinical trials conducted at Seoul National University Hospital and Ajou University Hospital demonstrated that the solution improved physicians' diagnostic sensitivity for cerebral aneurysms by more than 10 percentage points. Notably, for small aneurysms less than 3mm, the AI's diagnostic sensitivity was about 18 percentage points higher than that of physicians.

This solution is the first CT image-based AI medical device for cerebral aneurysm diagnosis in Korea. Cerebral aneurysms are examined using CTA (CT angiography) or MRA (magnetic resonance angiography). Compared to MRA, CTA offers much shorter examination times and lower costs, making it widely used in clinical practice. While some CT image-based AI solutions with FDA approval exist in the global market, all of them only detect aneurysms 4mm or larger, giving PurpleAI's solution a performance advantage.

Choi Jinwook, a professor of radiology at Ajou University Hospital who led the clinical research, stated, "Cerebral aneurysms are conditions that require careful attention from medical professionals due to their potential to cause severe cerebral hemorrhage and the difficulty of diagnosis. The high diagnostic sensitivity of this solution for small, hard-to-diagnose aneurysms is clinically significant."

Park Byungjun, CEO of PurpleAI, said, "With the Ministry of Food and Drug Safety's approval of our cerebral aneurysm diagnostic AI solution, following our existing AI solutions for cerebral hemorrhage and cerebral infarction diagnosis, we have established a comprehensive lineup of basic diagnostic solutions for acute stroke patients. We will further develop our platform to provide end-to-end support for stroke patient diagnostic workflows by expanding into detailed diagnosis and prognosis prediction."

This content was produced with the assistance of AI translation services.